{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:45:44Z","timestamp":1793306744668,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.sxmr.2015.10.004","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T16:46:51Z","timestamp":1454431611000},"page":"74-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["The Role of PDE5 Inhibitors and the NO\/cGMP Pathway in Cancer"],"prefix":"10.1093","volume":"4","author":[{"given":"Taylor C.","family":"Peak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2015.10.004_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.sxmr.2015.10.004_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/978-1-4939-1031-1_2","article-title":"sGC-cGMP signaling: target for anticancer therapy","volume":"814","author":"Bian","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.niox.2009.11.007","article-title":"Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation","volume":"22","author":"Mujoo","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.sxmr.2015.10.004_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(00)00256-4","article-title":"Role of nitric oxide in carcinogenesis and tumour progression","volume":"2","author":"Lala","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1096\/fasebj.11.6.9194524","article-title":"Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression","volume":"11","author":"Ambs","year":"1997","journal-title":"FASEB J"},{"key":"10.1016\/j.sxmr.2015.10.004_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I","article-title":"Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis","volume":"86","author":"Jadeski","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jnci\/89.6.421","article-title":"Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene","volume":"89","author":"Xie","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.sxmr.2015.10.004_bib8","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood.V87.12.5136.bloodjournal87125136","article-title":"Involvement of nitric oxide in target-cell lysis and DNA fragmentation induced by murine natural killer cells","volume":"87","author":"Filep","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.sxmr.2015.10.004_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrc1910","article-title":"The role of nitric oxide in tumour progression","volume":"6","author":"Fukumura","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib10","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/sj.onc.1209251","article-title":"Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase\/cGMP pathway in human ovarian cancer cells","volume":"25","author":"Fraser","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.sxmr.2015.10.004_bib11","first-page":"47","article-title":"Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3","volume":"12","author":"Saino","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.sxmr.2015.10.004_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/iub.1057","article-title":"NOS-2 signaling and cancer therapy","volume":"64","author":"Bian","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.sxmr.2015.10.004_bib13","series-title":"Cancer Facts & Figures\u00a02015","year":"2015"},{"key":"10.1016\/j.sxmr.2015.10.004_bib14","series-title":"Melanoma. Abeloff's Clinical Oncology","first-page":"1071","author":"Gangadhar","year":"2014"},{"key":"10.1016\/j.sxmr.2015.10.004_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sxmr.2015.10.004_bib16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.sxmr.2015.10.004_bib17","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib18","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma","volume":"63","author":"Dong","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib19","first-page":"3058","article-title":"3\u2032,5\u2032-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition","volume":"53","author":"Drees","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1755-148X.2009.00618.x","article-title":"Identification of direct transcriptional targets of (V600E)BRAF\/MEK signalling in melanoma","volume":"22","author":"Packer","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib21","first-page":"355","article-title":"Expression and role of phosphodiesterase 5 in human malignant melanoma cell line","volume":"30","author":"Murata","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.sxmr.2015.10.004_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.sxmr.2015.10.004_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1755-148X.2010.00819.x","article-title":"Melanoma and viagra: an unexpected connection","volume":"24","author":"Mitra","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib25","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/S1569-9056(15)60133-6","article-title":"Do PDE5 inhibitors increase the risk of malignant melanoma?","volume":"142","author":"Loeb","year":"2015","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.sxmr.2015.10.004_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0090-4295(98)00513-5","article-title":"Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis","volume":"53","author":"Goluboff","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2015.10.004_bib27","first-page":"994","article-title":"Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model","volume":"170","author":"Qian","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/aja.2012.162","article-title":"Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis","volume":"15","author":"Chavez","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2015.10.004_bib29","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/jama.291.13.1578","article-title":"Ejaculation frequency and subsequent risk of prostate cancer","volume":"291","author":"Leitzmann","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2015.10.004_bib30","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/en.2009-1411","article-title":"Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia","volume":"151","author":"Zenzmaier","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.sxmr.2015.10.004_bib31","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/1097-0142(20001101)89:9<2018::AID-CNCR19>3.3.CO;2-P","article-title":"Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study","volume":"89","author":"Movsas","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/onc.2008.476","article-title":"Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer","volume":"28","author":"Khandrika","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.sxmr.2015.10.004_bib33","first-page":"479","article-title":"Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy","volume":"193","author":"Michl","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib34","doi-asserted-by":"crossref","first-page":"1236361","DOI":"10.1126\/science.1236361","article-title":"Autonomic nerve development contributes to prostate cancer progression","volume":"341","author":"Magnon","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.sxmr.2015.10.004_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2004.09.002","article-title":"Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure","volume":"47","author":"Palisaar","year":"2005","journal-title":"Eur Urol"},{"issue":"4 Pt 1","key":"10.1016\/j.sxmr.2015.10.004_bib36","first-page":"1328","article-title":"The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy","volume":"172","author":"Ward","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib37","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2015.02.002","article-title":"A\u00a0detailed analysis of the association between postoperative phosphodiesterase Type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy","volume":"68","author":"Gallina","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0959-8049(02)00040-0","article-title":"The APC gene in colorectal cancer","volume":"38","author":"Fodde","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib39","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/onc.2010.91","article-title":"PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4","volume":"29","author":"Kwon","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.sxmr.2015.10.004_bib40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","article-title":"Cyclooxygenase regulates angiogenesis induced by colon cancer cells","volume":"93","author":"Tsujii","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.sxmr.2015.10.004_bib41","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","article-title":"Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis","volume":"328","author":"Giardiello","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2015.10.004_bib42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/1940-6207.CAPR-11-0559","article-title":"A\u00a0novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity","volume":"5","author":"Whitt","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.sxmr.2015.10.004_bib43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jcb.20286","article-title":"Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells","volume":"94","author":"Zhu","year":"2005","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.sxmr.2015.10.004_bib44","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1940-6207.CAPR-10-0030","article-title":"Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition","volume":"3","author":"Tinsley","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.sxmr.2015.10.004_bib45","first-page":"3338","article-title":"Exisulind induction of apoptosis involves guanosine 3\u2032,5\u2032-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin","volume":"60","author":"Thompson","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/cdd.2013.163","article-title":"Type 2 cGMP-dependent protein kinase regulates homeostasis by blocking c-Jun N-terminal kinase in the colon epithelium","volume":"21","author":"Wang","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.sxmr.2015.10.004_bib47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.arcmed.2012.08.006","article-title":"Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors","volume":"43","author":"Karami-Tehrani","year":"2012","journal-title":"Arch Med Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib48","first-page":"6096","article-title":"Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative","volume":"63","author":"Harris","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10552-007-9003-y","article-title":"NSAIDs and breast cancer recurrence in a prospective cohort study","volume":"18","author":"Kwan","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.sxmr.2015.10.004_bib50","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/beta-catenin-mediated transcription in human breast tumor cells","volume":"4","author":"Tinsley","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.sxmr.2015.10.004_bib51","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1158\/1535-7163.MCT-09-0758","article-title":"Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G","volume":"8","author":"Tinsley","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.sxmr.2015.10.004_bib52","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1111\/j.1742-4658.2011.08260.x","article-title":"Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines","volume":"278","author":"Fallahian","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.sxmr.2015.10.004_bib53","first-page":"2039","article-title":"Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK\/JNK signal transduction in breast cancer cells","volume":"27","author":"Lan","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.sxmr.2015.10.004_bib54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/bjc.1997.414","article-title":"The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer","volume":"76","author":"Nooter","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/bjc.1995.274","article-title":"Nitric oxide synthase activity in human breast cancer","volume":"72","author":"Thomsen","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib56","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jcp.2004.023028","article-title":"Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour","volume":"58","author":"Tse","year":"2005","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2012.10.545","article-title":"Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: implications for breast cancer","volume":"57","author":"Sen","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.sxmr.2015.10.004_bib58","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ijc.11268","article-title":"Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase","volume":"106","author":"Jadeski","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.sxmr.2015.10.004_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1182\/blood-2002-01-0075","article-title":"Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells","volume":"101","author":"Sarfati","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.sxmr.2015.10.004_bib60","first-page":"787","article-title":"67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis","volume":"123","author":"Kumazoe","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.sxmr.2015.10.004_bib61","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjh.13135","article-title":"Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cells","volume":"168","author":"Kumazoe","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib62","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.febslet.2013.07.041","article-title":"Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis","volume":"587","author":"Kumazoe","year":"2013","journal-title":"FEBS Lett"},{"key":"10.1016\/j.sxmr.2015.10.004_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res United States"},{"key":"10.1016\/j.sxmr.2015.10.004_bib64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.sxmr.2015.10.004_bib65","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.sxmr.2015.10.004_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1006\/bbrc.2000.4221","article-title":"Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site","volume":"280","author":"Lin","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.sxmr.2015.10.004_bib67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2008.06.122","article-title":"PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model","volume":"1230","author":"Black","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib68","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1073\/pnas.1006965107","article-title":"Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction","volume":"107","author":"Das","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sxmr.2015.10.004_bib69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-010-0765-7","article-title":"Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells","volume":"124","author":"Di","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.sxmr.2015.10.004_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2015.10.004_bib71","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1158\/0008-5472.CAN-10-3820","article-title":"Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2015.10.004_bib72","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1349-7006.2012.02328.x","article-title":"PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Ccassette C10) transporter","volume":"103","author":"Chen","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.sxmr.2015.10.004_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/mol.113.090043","article-title":"Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal\/genitourinary cancer cells","volume":"85","author":"Booth","year":"2014","journal-title":"Mol Pharmacol"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052115000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052115000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:36:19Z","timestamp":1672774579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052115000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S2050052115000050"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2015.10.004","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of PDE5 Inhibitors and the NO\/cGMP Pathway in Cancer","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2015.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}